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ZeNan L. Chang1,2, Pamela A. Silver3 and Yvonne Y. Chen1*Abstract
Background: T cells expressing chimeric antigen receptors (CARs) have shown exciting promise in cancer therapy,
particularly in the treatment of B-cell malignancies. However, optimization of CAR-T cell production remains a
trial-and-error exercise due to a lack of phenotypic benchmarks that are clearly predictive of anti-tumor functionality. A
close examination of the dynamic changes experienced by CAR-T cells upon stimulation can improve understanding
of CAR–T-cell biology and identify potential points for optimization in the production of highly functional T cells.
Methods: Primary human T cells expressing a second-generation, anti-CD19 CAR were systematically examined for
changes in phenotypic and functional responses to antigen exposure over time. Multi-color flow cytometry was
performed to quantify dynamic changes in CAR-T cell viability, proliferation, as well as expression of various activation
and exhaustion markers in response to varied antigen stimulation conditions.
Results: Stimulated CAR-T cells consistently bifurcate into two distinct subpopulations, only one of which (CARhi/CD25+)
exhibit anti-tumor functions. The use of central memory T cells as the starting population and the resilience—but
not antigen density—of antigen-presenting cells used to expand CAR-T cells were identified as critical parameters
that augment the production of functionally superior T cells. We further demonstrate that the CARhi/CD25+ subpopulation
upregulates PD-1 but is resistant to PD-L1-induced dysfunction.
Conclusions: CAR-T cells expanded ex vivo for adoptive T-cell therapy undergo dynamic phenotypic changes during the
expansion process and result in two distinct populations with dramatically different functional capacities. Significant and
sustained CD25 and CAR expression upregulation is predictive of robust anti-tumor functionality in antigen-stimulated
T cells, despite their correlation with persistent PD-1 upregulation. The functionally superior subpopulation can be
selectively augmented by careful calibration of antigen stimulation and the enrichment of central memory T-cell type.
Keywords: Chimeric antigen receptor, CD19 CAR-T cell, T-cell immunotherapy, PD-1Background
Adoptive cell therapy using T cells engineered to express
tumor-targeting chimeric antigen receptors (CARs) is a
promising treatment strategy for refractory diseases such
as metastatic melanoma, leukemia, and neuroblastoma
[1–3]. Several recent trials have demonstrated remark-
able clinical efficacy, particularly in the treatment of
chronic and acute B-cell malignancies using CD19-
targeting T cells [4–6]. Accumulating clinical reports* Correspondence: yvonne.chen@ucla.edu
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creativecommons.org/publicdomain/zero/1.0/suggest that, in addition to patient-to-patient variations in
tumor burden and overall health profile, the quality of
individual T-cell products could significantly influence
clinical outcome [5, 7]. However, it remains unclear which
T-cell characteristics are the most critical and predictive
of anti-tumor efficacy, and if and how such characteristics
could be promoted during T-cell manufacturing. As CAR-T
cell technology advances toward broader clinical use, the
ability to identify critical T-cell characteristics and sys-
tematically optimize CAR-T cell preparation has the po-
tential to significantly improve the robustness of adoptive
T-cell therapy.ticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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ing protocols utilized thus far by different clinical groups,
rendering efforts to systematically optimize the produc-
tion process a practical challenge. Although numerous
characterization assays and product release criteria are ap-
plied to CAR-T cell products, they typically generate snap-
shot views of T-cell properties and provide limited insight
into dynamic changes experienced by T cells, which may
occur throughout in vitro expansion as well as after infu-
sion into the patient. For example, phenotypic characteris-
tics such as % CD3+, % CD4+, % CD8+, and % CAR+ are
typically quantified at the end of cell expansion prior to
product release for infusion [4–6, 8]. Cytokine production
and cell lysis efficiency are measured in vitro at single time
points to confirm target-specific functional activity [5, 6, 9].
After adoptive transfer, in vivo performance is measured
by quantifying cytokine levels, tumor burden, and CAR+
T-cell count in the patient [4, 10, 11]. In these cha-
racterization assays, observed anti-tumor functionality is
attributed to CAR+ T cells as a homogenous group,
and time-point data are used to generalize across cell-
expansion and treatment periods. Given that current
clinical protocols typically utilize unsorted, polyclonal T
cells for infusion, the assumption of uniformity among
CAR+ T cells is one dictated by experimental constraints
rather than our understanding of CAR–T-cell biology. In-
deed, the recognition that not all T cells are equal has
prompted active research on questions such as the opti-
mal T-cell subtype and cytokine regimen to use for the
production of therapeutic T cells [12–16]. However, trial-
and-error remains the dominant approach to process
optimization, as typical characterization methods such as
those described above provide information that enables
quality control but not in-depth understanding of how the
T cells arrived at their present state of functionality or lack
thereof. We propose that a close examination of dynamic
changes experienced by CAR-T cells throughout a stimula-
tion cycle can provide a deeper understanding of CAR–
T-cell biology and identify potential points for optimization
in the production of highly functional therapeutic T cells.
In this study, we perform quantitative evaluations of
the phenotypic and functional changes exhibited by
CAR-T cells undergoing antigen stimulation, including
CAR–T-cell viability, proliferation, as well as the expres-
sion of various T-cell activation and exhaustion markers.
Contrary to the assumption of uniformity, stimulated
CAR+ T cells consistently bifurcate into two distinct
populations, only one of which (CARhi/CD25+) is func-
tionally active. Detailed in vitro examinations reveal dy-
namic changes in CAR-T cells over the course of antigen
stimulation that are difficult to observe in vivo, and en-
able the identification of strategies to maximize the
CARhi/CD25+ cell subpopulation upon antigen stimula-
tion. Finally, we demonstrate that CAR-T cells in thefunctionally superior subpopulation upregulate PD-1 but
remain functional when challenged by target cells over-
expressing PD-L1, indicating an unexpected source of
CAR-T cell resilience and highlighting properties to be
considered in the development of combinatorial stra-
tegies employing CAR-T cells and checkpoint therapies.
Methods
Cell line isolation and maintenance
Primary human CD4+ or CD8+ T cells were isolated
from healthy donor blood samples obtained from the
Boston Children’s Hospital Blood Donor Center and the
UCLA Blood & Platelet Center. The RosetteSep CD4+ or
CD8+ Human T-cell Enrichment Cocktail (Stemcell
Technologies) was used following manufacturer’s proto-
cols. Central memory T cells were obtained by magnetic
bead-based sorting. Anti-CD45RA MicroBeads (Miltenyi
Biotec) were used to deplete CD45RA+ cells, and
CD45RA− cells were stained with anti-CCR7-APC (clone
G043H7, BioLegend) followed by anti-APC MicroBeads
(Miltenyi Biotec) and enriched for CCR7+ cells. Isolated
T cells were seeded at 1 × 106 cells/ml in T-cell media
(RPMI-1640 media (Lonza) with 10 % heat-inactivated
fetal bovine serum (FBS; Life Technologies)) and stimu-
lated with CD3/CD28 Dynabeads (Life Technologies) at
a 1:1 cell:bead ratio. Cells were fed 50 IU/ml interleukin
(IL)-2 (Chiron) and 1 ng/ml IL-15 (Miltenyi Biotec)
every 48 h and passaged routinely. H9 and JeKo-1 cells
were obtained from ATCC and maintained in RPMI-1640
with 10 % or 20 % heat-inactivated FBS, respectively.
K562, TM-LCL, and Raji cells were generous gifts from
Dr. Michael C. Jensen at Seattle Children’s Research Insti-
tute and maintained in T-cell media. CD19+ K562 and
CD19+ H9 cells were generated by lentivirally transducing
parental K562 and H9 cells with CD19 cDNA expressed
from an EF1α promoter and sorting for CD19+ cells by
fluorescence-activated cell sorting (FACS).
Generation and isolation of CAR-expressing T cells
Lentivirus was produced as previously described [17].
T-cells stimulated with CD3/CD28 Dynabeads for 3 days
were transduced at a multiplicity of infection of 3 with
1 × 106 T cells/500 μl/well in a 24-well plate and supple-
mented with 50 IU/ml IL-2, 1 ng/ml IL-15, and 5 μg/ml
polybrene (Sigma Aldrich). No virus was added to the
mock-transduced control. The plate was centrifuged at
800 × g for 30 min at room temperature with slow accel-
eration and no brake. Cells were fed fresh media with
cytokines on day 2 post transduction, washed on day 3,
and maintained as described above until Dynabead re-
moval on day 6 post transduction. To obtain EGFRt+
(CAR+) populations, transduced cells were stained with
biotinylated Erbitux (Bristol-Myers Squibb; biotinylated
in house) followed by magnetic sorting using anti-Biotin
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facturer’s protocols. CAR+ T-cell fractions with different
CAR expression levels were isolated by staining transduced
cells with biotinylated Erbitux followed by streptavidin-PE
(Jackson Immunoresearch), then sorted by FACS. Re-
gardless of sorting method, CAR+ cells were expanded as
previously described [18]. Briefly, 1 × 106 T cells were re-
suspended in 50 ml total volume with 7 × 106 γ-irradiated
(80 Gy) TM-LCL cells and supplemented with 50 IU/ml
IL-2 and 1 ng/ml IL-15 every 48 h. Stimulated high and
low CAR-expressing populations were isolated by FACS
after 20 h of co-incubation with CD19+ K562 target cells
at a 2:1 effector-to-target (E:T) ratio.Surface marker staining
For surface marker staining, 1 × 105 T cells were seeded in
96-well plates with indicated target cells (unirradiated) at
a 2:1 E:T ratio unless otherwise noted. Experiments
with 2.5 × 105 T cells were performed in 24-well plates.
When indicated, γ-irradiated (100 Gy) K562 targets were
used. When indicated, CD28 monoclonal antibody (clone
CD28.2; eBiosciences) was applied at 10 μg/mL to provide
CD28 costimulatory signal. Cell mixtures were incubated at
37 °C, and analyzed at the indicated time points with
fluorescently labeled monoclonal antibodies binding CCR7
(clone REA108), CD19 (clone LT19), CD25 (clone BC96),
CD27 (clone M-T271), CD45RA (clone T6D11), CD57
(clone TB03), PD-1 (PD1.3.1.3), PD-L1 (clone 29E.2A3),
and Tim-3 (clone F38-2E2) (BioLegend and Miltenyi
Biotec). V500-conjugated Annexin V (BD Biosciences) and
Pacific Blue-conjugated Annexin V (BioLegend) were used
to detect pre-apoptotic cells. CAR expression was probed
with Protein L (Genscript) followed by PE-conjugated strep-
tavidin (Jackson Immunoresearch) or with APC-conjugated
polyclonal antibody binding human IgG Fcγ (Jackson
Immunoresearch). EGFRt expression was probed with
biotinylated Erbitux followed by PE-conjugated strep-
tavidin. Analyses were performed on a MACSQuant VYB
flow cytometer (Miltenyi Biotec) equipped with 405-, 488-,
and 561-nm lasers. Data were processed using FlowJo soft-
ware (TreeStar).Cell proliferation and cytokine production quantification
T cells were labeled with 0.2 μM carboxyfluorescein dia-
cetate succinimidyl ester (CFDA-SE, Life Technologies)
for cell proliferation tracking. A human Th1/Th2 cyto-
kine cytometric bead array kit (BD Biosciences) was used
according to the manufacturer’s protocols to quantify
cytokine secretion. Co-incubations with target cells were
set up as described above. Samples were analyzed with a
MACSQuant VYB flow cytometer and cytokine produc-
tion was quantified using the FCAP Array 3.0 software
(Soft Flow).Quantitative PCR
Genomic DNA and cDNA were isolated from frozen
T-cell pellets with DNeasy Blood and Tissue Kit (Qiagen)
and SuperScript III CellsDirect cDNA Synthesis System
(Life Technologies), respectively. Quantitative PCR (qPCR)
was performed using SsoFast EvaGreen Supermix (Bio
Rad), a CFX96 Real-Time Thermal Cycler (Bio Rad), and
WPRE forward and reverse primers (5′-TTTCCGGGA
CTTTCGCTTTC and 5′-AAGGGACGTAGCAGAAG
GAC, respectively, for cDNA; or 5′-ACTGTGTTTGCT
GACGCAACCC and 5′-CAACACCACGGAATTGTCA
GTGCC, respectively, for gDNA) according to the ma-
nufacturer’s protocols. The reference β-actin primer set
5′-TCCCTGGAGAAGAGCTACGA (forward) and 5′-AG
CACTGTGTTGGCGTACAG (reverse) provided norma-
lization control. The qPCR protocol included 30 cycles of
a 5-s denaturation step at 95 °C for cDNA and 98 °C for
gDNA, and a 5-s annealing/extension step at 60 °C. All re-
actions were performed in quadruplicates, and threshold
cycle (Ct) values were averaged to obtain the arithmetic
mean. Relative WPRE levels were calculated with the fol-
lowing formula:
RL¼ εActinð Þ
Ct; Actin
εWPREð ÞCt; WPRE
where RL indicates relative WPRE levels, εx indicates
primer efficiency for gene x, and Ct,x indicates the aver-
aged Ct value for gene x. Standard deviation in relative
WPRE levels was calculated with the following formula:
s:d:¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
RL lnεActinð Þ2 s:d:Actinð Þ2þ RL lnεWPREð Þ2 s:d:WPREð Þ2
q
where s.d.x indicates the standard deviation calculated
from the quadruplicate samples for gene x.
Statistical methods
Data are presented as means ± standard deviations as
stated in figure legends. Results were analyzed by two-
tailed unpaired Student’s t test with simple Bonferroni cor-
rection for multiple comparisons when appropriate. Tests
were conducted with statistical significance set at p < 0.05.
Results
Antigen stimulation results in the emergence of CARhi cells
To investigate the degree of heterogeneity among CAR-T
cells, CAR constructs were stably integrated into bulk
primary human CD8+ T cells via lentiviral transduction.
Unless otherwise indicated, an anti-CD19 CAR containing
CD28 as the co-stimulatory domain was used [19], and a
truncated epidermal growth factor receptor (EGFRt) was
linked to the CAR via a T2A peptide (Fig. 1a). In this con-
figuration, CAR and EGFRt are transcribed as a single
mRNA but translated into two separate proteins, allowing
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Fig. 1 A CARhi/CD25+ population emerges upon antigen stimulation of CAR-T cells. a Schematic of the second-generation anti-CD19 CAR with CD28
co-stimulatory domain; cyto: cytoplasmic domain; EGFRt: truncated EGFR peptide; LTR: long terminal repeats; RRE: Rev responsive element; tm: transmembrane
domain; scFv: single chain variable fragment; T2A: Thosea asigna virus 2A peptide; WPRE: woodchuck hepatitis virus posttranscriptional response
element. b-e CD8+ T cells expressing various CARs separate into CARhi/CD25+ and CARlo/CD25− populations within 24 h of antigen or CD3/CD28
stimulation. T cells expressing anti-CD19 CARs with b CD28 or c 4-1BB co-stimulation domain or d an anti-CD20 CAR with 4-1BB all result in population
polarization upon stimulation with K562 target cells expressing cognate antigens. e CAR–T-cell stimulation with magnetic beads coated with anti-CD3
and anti-CD28 antibodies also yields bifurcated populations
Chang et al. Journal of Translational Medicine  (2015) 13:161 Page 4 of 16quantification of CAR expression via antibody staining of
surface-bound EGFRt, without disrupting potential interac-
tions between CAR molecules and their ligands [20]. Co-
staining experiments confirmed that EGFRt staining tightly
correlates with direct CAR staining in both stimulated and
unstimulated CAR-T cells (Additional file 1: Figure S1).
EGFRt is particularly useful to track the expression of the
anti-CD19 CAR in this study because the anti-CD19 scFv
used is only weakly stained by reagents such as protein L
and anti-Fab antibody that typically bind scFvs. Unless spe-
cified otherwise, we have used EGFRt to measure CAR ex-
pression in the studies reported here.
CAR-T cells were co-incubated with parental (CD19−)
or CD19+ K562 target cells and monitored for five days. A
CARhi/CD25+ group with elevated CAR expression con-
sistently emerged within 24 h of co-incubation, resulting
in a population distinct from the CARlo/CD25− group,
which maintained the original CAR expression level
(Fig. 1b–d). This population bifurcation is observed in
both CD4+ and CD8+ T cells (Fig. 1b and Additional file 2:
Figure S2), is independent of the co-stimulatory signals
present in the CAR (either CD28 or 4-1BB; Fig. 1b, c), and
is not restricted to a particular antigen (either CD19 or
CD20; Fig. 1c, d). We also observed the emergence of
CARhi cells after stimulating CAR-T cells with CD3/CD28
beads (Fig. 1e), indicating that the population bifurcation
is not unique to antigen presentation by K562 cells or to
the CAR signaling domain. Instead, it also occurs when
T cells are stimulated via the endogenous T-cell receptor
(TCR)/CD28 machinery. In all instances studied, CARlo
cells exhibited low or no expression of the activation
marker CD25 while CARhi cells showed robust CD25upregulation (Fig. 1b–e), suggesting distinct activation
states for the CARhi and CARlo populations.
CARhi but not CARlo cells exhibit robust T-cell functions
Given their differences in CD25 expression, we hypothe-
sized that the CARhi subpopulation is productively acti-
vated while CARlo cells remain inactive or are anergized.
During co-incubation with CD19+ target cells in the
absence of exogenous cytokines, CD8+ T cells expressing
the CD19 CAR undergo a rapid and dramatic initial
decline in viable T-cell count, followed by a population
rebound in which CARhi cells emerge as the dominant
T-cell group (Fig. 2a), consistent with the hypothesis that
only CARhi cells are productively activated. In contrast,
mock-transduced T cells as well as CAR-T cells co-
incubated with parental (CD19−) K562 cells show a gra-
dual decline in viable T-cell count without changes in
CAR expression level, indicating that the dynamic popula-
tion changes observed in Fig. 2a are specifically triggered
by antigen stimulation. Primary CD4+ CAR-T cells as well
as mixed CD4+ and CD8+ CAR-T cells show the same pat-
terns of population dynamics (Additional file 3: Figure
S3), demonstrating that the behavior is not unique to the
CD8+ phenotype and is also representative of mixed CD4+
and CD8+ T cells typically used in therapeutic settings.
CFSE dilution and Annexin V staining results demon-
strate that CARhi cells proliferate robustly with minimal
apoptosis; in contrast, CARlo cells divide at the same low
rate as unstimulated CAR-T cells, and exhibit increased
cell death compared to both CARhi and unstimulated cells
(Fig. 2b, c). These results further support the hypothesis
that the CARlo cells, despite expressing a second-
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Fig. 2 Antigen-stimulated CAR-T cells undergo selective expansion of the CARhi compartment. CFSE-labeled, CD8+ CAR-expressing cells or mock-transduced
(CAR−) T cells were co-incubated with parental (CD19−) or CD19+ K562 targets without exogenous cytokines and monitored for a total T-cell count (left red
axis) and CARhi or CARlo as a fraction of total CAR-T cells (right black axis), b median CFSE intensity, and c Annexin V staining. Average values of
triplicates are shown with error bars indicating ± 1 standard deviation (s.d.)
Chang et al. Journal of Translational Medicine  (2015) 13:161 Page 5 of 16generation CAR containing a co-stimulation domain, have
not been properly activated.
In addition to differences in proliferative potentials,
CARhi cells exhibit clearly superior functional profiles com-
pared to CARlo cells. The two CD19 CAR-T cell popula-
tions were separated by FACS after 20 h of co-incubation
with CD19+ K562 target cells. Multiplex cytokine measure-
ments revealed robust Th1 cytokine production by CARhi
cells during the 24-h period following cell sorting (Fig. 3a).
In contrast, CARlo cells produced relatively high levels of
IFN-γ but not TNF-α or IL-2, consistent with previous
study reporting the ability of anergic T cells to produce
IFN-γ but not IL-2 [21] (Fig. 3a).0
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killers of tumor cells in successfully treated patients [4],
and the ability to maintain functionality in the face of
high tumor burden and repeated stimulation is critical
to the therapeutic efficacy of CAR-T cells. Upon re-
exposure to target cells, sorted CD8+ CARlo T cells
showed minimal target-cell lysis (Fig. 3b). In contrast,
CD8+ CARhi T cells rapidly eliminated CD19+ K562 tar-
gets, achieving even more complete target clearance
than unsorted CAR-T cells (Fig. 3b). Both T-cell popula-
tions underwent a contraction in viable T-cell count
upon antigen exposure, but CARhi cells greatly outper-
formed CARlo cells in subsequent proliferation (Fig. 3c).0
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creted the Th1 cytokines TNF-α and IL-2 upon antigen
re-challenge (Fig. 3d). As previously observed, CARlo
cells retained the ability to produce IFN-γ (Fig. 3d). The
contrasts between CARhi and CARlo cells described
above were also observed among CD4+ CAR-T cells
(Additional file 4: Figure S4), indicating the functional
disparities observed are intrinsic to CARhi vs. CARlo
subpopulations and are not restricted to the CD8+
phenotype. The clear functional superiority of CARhi
cells suggests that maximization of CARhi cells within a
given CAR-T cell preparation may enhance the anti-
tumor potential of the cell product. We next explored
the source of the CARhi phenotype and methods to
direct the T cell population toward this functional subset.
The CARhi phenotype is a transient state of activation
induced by antigen stimulation
Efforts to maximize CARhi cells require knowledge of
their origin. One possibility is that CARhi cells are gene-
tically encoded with higher CAR copy numbers, and
their superior proliferative capability enables their rapid
enrichment after antigen stimulation, despite their appa-
rent absence from the original CAR+ T-cell population.
Alternatively, CARhi cells may be genetically similar
to CARlo cells, but productive stimulation results in a
distinct, activated state. To distinguish between these
two possibilities, CD8+ T cells were sorted into three
populations with different CAR expression levels prior1.00 x
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After cell expansion over 9 days in culture, qPCR per-
formed on genomic DNA confirmed significant diffe-
rences in the copy number of the CAR transgene in the
three populations (Fig. 4a). Upon antigen stimulation, all
three populations were able to generate CARhi cells with
clearly elevated CAR expression (Fig. 4b). In fact, T cells
with the lowest CAR genomic copy number yielded the
highest % CARhi and the highest CD25 expression level
among CARhi cells upon antigen stimulation (Fig. 4b),
indicating that a high genetic copy number of the CAR
transgene is neither essential nor automatically condu-
cive to the emergence of the CARhi phenotype.
Quantitative PCR performed on sorted CARhi and
CARlo cells showed that CARhi and CARlo cells differ
slightly in genomic copy numbers of the CAR construct
(Fig. 5a). However, the two populations diverge more
prominently in CAR transcription levels, with CARhi
cells overexpressing the anti-CD19 CAR mRNA by 3.5
folds (CD4+ T cells) or 7.5 folds (CD8+ T cells) com-
pared to CARlo cells (Fig. 5a). In addition, CAR expres-
sion levels in CARhi cells return to baseline (i.e., the
same level as unstimulated and CARlo cells) within days
after the removal of antigen stimulation (Fig. 5b), indi-
cating that the CARhi phenotype is predominantly due
to transient upregulation of CAR expression. Further-
more, antigen-stimulated CAR-T cells upregulate the
surface expression of both CAR and EGFRt, which are
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quadruplicates with error bars indicating ± 1 s.d.; all other plots show
average values of triplicates with error bars indicating ± 1 s.d.
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S1D). This result indicates that the increase in CAR sur-
face expression is not due to CAR-specific changes in
post-translational processes such as surface localization,
receptor endocytosis, or protein degradation. Taken to-
gether, these data indicate that elevated CAR expression
in CARhi cells is mainly a result of transient CAR tran-
script upregulation in response to cell activation, and that
increasing the copy number of the CAR transgene is un-
likely to be the most effective means of promoting the
CARhi phenotype.Overstimulation results in loss of the CARhi phenotype
One approach to maximizing CARhi cells is to prevent the
dysfunctional CARlo state. Given that the CARhi pheno-
type is induced by antigen stimulation, we next investi-
gated whether the CARlo cells fail to upregulate CAR
expression because they experienced inadequate stimula-
tion or if they became exhausted due to overstimulation.
When sorted CARhi cells were re-challenged with antigen,
the majority retained elevated CAR expression but a small
population fell into the CARlo gate (Fig. 6), suggesting that
repeated antigen exposure anergized a minority of the
CARhi cells. Meanwhile, a large portion of CARlo cells ex-
perienced further reduction in CAR expression and no
cells moved into the CARhi regime upon antigen re-
challenge (Fig. 6). These results support the hypothesis
that a sufficiently strong stimulation is required for the
CARhi phenotype, but overstimulation results in the ex-
haustion of activated cells and a decline into the dysfunc-
tional CARlo/CD25− state. Additional antigen challenge to
CARlo cells would only further decrease CAR expression
and T-cell functionality. These results are consistent with
our previous observation that T cells with the highest gen-
omic copy number of the CAR transgene (and thus the
highest capacity to receive antigen stimulation) yielded the
largest proportion of CARlo cells after antigen stimulation
(Fig. 4b). Therefore, maximization of the CARhi popula-
tion requires precise calibration of antigen stimulation,
and a systematic approach to this task would facilitate the
optimization of the cell production process.
Persistent antigen stimulation facilitates CARhi expansion
Several stimulation conditions were evaluated to deter-
mine an effective protocol for the preparation of T cells
with the CARhi phenotype. Since co-stimulation plays a
major role in achieving productive T-cell activation, we
first examined whether additional co-stimulation could
enhance CARhi development and forestall the emergence
of non-functional CARlo cells. However, supplementing a
CD28 agonist antibody to CAR-T cells immediately prior
to antigen exposure did not significantly alter the CARhi
vs. CARlo distribution dynamics nor impact the absolute
CARhi cell numbers (Additional file 6: Figure S6).
T-cell expansion with the aid of antigen-presenting
feeder cells is a well-established method for CAR-T cell
preparation [18, 22, 23]. We next evaluated multiple
feeder cell lines for their ability to support CARhi/CD25+
cell generation (Fig. 7a–c). CD8+ CAR-T cells were co-
incubated at a 2:1 effector-to-target (E:T) ratio with se-
veral CD19+ target cell lines, including naturally CD19+
JeKo-1, Raji, and TM-LCL cells, as well as K562 and H9
cells modified to stably express CD19. Besides JeKo-1
cells, which were depleted rapidly, all target cell lines
tested resulted in the emergence of CARhi cells, and
CARhi expression was always correlated with CD25
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all CARhi cells upregulated the activation marker equally
(Fig. 7c). Considering both the number of CARhi/CD25+
cells and the intensity of CD25 expression (Fig. 7b, c),
the results suggest CD19+ K562 and TM-LCL cells are
both suitable candidates as feeder cells for CD19 CAR-T
cell expansion. Interestingly, these two cell lines are also
the most resistant to CAR-T cell–mediated lysis among
the target cell lines tested (Fig. 7a). In contrast, antigen ex-
pression level on target cells shows no correlation with
the target cells’ susceptibility to T-cell–mediated lysis or
with CARhi cell development (Additional file 8: Figure S8).
Therefore, it is the persistence of antigen presentation ra-
ther than the antigen density on individual target cells that
predicts CARhi emergence patterns. The most resilient
target cell line, CD19+ K562, resulted in a relatively small
CARhi population at early time points, but the total num-
ber and CD25 expression level of CARhi cells increased
steadily throughout subsequent days, confirming CD19+
K562 as an effective trigger for the functional CARhi
phenotype (Fig. 7a—c).
To more precisely evaluate the impact of target-cell dos-
age on CAR–T-cell bifurcation, we co-incubated CD8+
CAR-T cells with CD19+ K562 targets at 1:2, 2:1, 5:1, and
10:1 E:T ratios. Results corroborate the observation that
sustained production of CARhi cells requires high target-
cell inputs that enable persistent antigen presentation
(Fig. 7d). CAR-T cells treated with the largest number of
antigen-presenting cells ultimately resulted in the highest
median CD25 expression level among CARhi cells, but
only after a steady rise over time as previously observed
(Fig. 7e). These observations hold true regardless of
whether the target cells were irradiated prior to co-
incubation with CAR-T cells (Additional file 9: Figure S9),
confirming the applicability of this evaluation method
to CAR-T cell expansion protocols employed in clinical
settings.
CARhi cells are PD-1+ but resist PD-L1-induced dysfunction
The observation that sustained antigen stimulation is re-
quired for the maintenance of the CARhi phenotype
(Figs. 5b and 7b, d) raises the question of whether CARhi
cells are at risk of exhaustion, leading to lower the-
rapeutic efficacy despite their functional capabilities
in vitro. Indeed, surface antibody staining revealed that
CARhi cells upregulate PD-1, a marker whose sustained
expression is generally associated with T-cell dysfunction
[24] (Fig. 8). Furthermore, CARhi cells generated through
stimulation by the most resilient antigen-presenting target
cells (CD19+ K562) and the highest antigen concentra-
tion (1:2 E:T ratio) also express the highest levels of
PD-1 (Fig. 8). Although it is unsurprising that antigen-
stimulated cells upregulate PD-1, our target-cell lysis,
T-cell proliferation, and cytokine production assay resultsdid not reveal any sign of dysfunction among the PD-1+
CARhi cells (Fig. 3), contrary to previous reports on PD-1+
tumor-targeting T cells [25–28]. One possible expla-
nation is that the target cell line used in this study
(K562) did not express high levels of PD-L1 (Additional
file 10: Figure S10A). To investigate this possibility, the
CD19+ K562 target line was engineered to stably over-
express PD-L1 (Additional file 10: Figure S10) and used
in weeklong co-incubation assays with both CD4+ and
CD8+ CD19 CAR-T cells.
CD8+ CAR-T cells monitored over seven days of co-
incubation in the absence of exogenous cytokines showed
no susceptibility to high PD-L1 expression on target cells,
demonstrating little to no changes in % CARhi, % Annexin
V+, CD25 and Tim-3 expression, T-cell proliferation, and
target-cell lysis efficiency (Fig. 9). A small but statistically
significant reduction in PD-1 expression was observed in
CD8+ CAR-T cells upon co-incubation with PD-L1+ target
cells (Fig. 9e). CARhi expression was consistently corre-
lated with increased CD25, PD-1, and Tim-3 expression
(Additional file 11: Figure S11), but high levels of PD-L1
on target cells did not result in reduced proliferative or
target-cell lysis response by CD8+ CAR-T cells over the
7-day observation period (Fig. 9f, g). It should be noted
that since CD8+ CAR-T cells are capable of eliminating
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added to the co-incubation culture at 48 and 96 h to en-
sure sustained exposure of CAR-T cells to PD-L1 presen-
tation by target cells. This continuous PD-L1 presentation
did not result in noticeable impact on CD8+ CAR-T cell
function. However, the repeated antigen challenge did re-
sult in a decline in CARhi cells relative to CARlo cells at
144 h (Fig. 9a), consistent with our previous observation
that overstimulation contributes to the loss of the func-
tional CARhi population (Fig. 6).
PD-L1 expression protected target cells from CD4+
CAR–T-cell lysis at early time points (Fig. 9g), potentially
due to the higher PD-1 expression level in CD4+ cells
compared to CD8+ cells (Additional file 12: Figure S12).
However, the resistance to CD4+ T-cell–mediated lysis ex-
hibited by PD-L1+ target cells appeared to be temporary,
and PD-L1 expression on target cells did not impact any
of the other T-cell parameters quantified (Fig. 9). No tar-
get cells beyond the initial input were added to the CD4+
culture since CD4+ CAR-T cells did not eliminate the
original target population. Taken together, the resultsindicate that CARhi cells persistently upregulate PD-1 ex-
pression but are not functionally impaired by PD-L1 pres-
entation on K562 target cells.
CAR-T cells generated from TCM subset are primed for the
CARhi/CD25+ phenotype
As demonstrated above, antigen stimulation is an integral
part of CAR-T cell preparation and its calibration can sig-
nificantly influence the efficiency of CARhi generation.
Another important parameter in CAR-T cell preparation
is the specific subtype of T cells used to make CAR-T cells.
Surface antibody staining revealed that the CARhi popula-
tion is enriched in central memory T (TCM) cells while the
CARlo population consists of predominantly effector (TE)
and effector memory T (TEM) cells (Fig. 10a). We thus in-
vestigated whether enrichment for TCM cells prior to CAR
transgene transduction may increase the CAR-T cells’ po-
tential to attain the CARhi phenotype.
From the same healthy donor’s blood sample, bulk
CD8+ T cells and CD8+ TCM (CCR7
+/CD45RA−) cells
were isolated separately (Additional file 13: Figure S13A),
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Fig. 10 TCM-derived CAR-T cells produce more CAR
hi T cells. a Bulk T-cell–derived CD4+ and CD8+ CAR-T cells were co-incubated with CD19+
K562 target cells without exogenous cytokines, and T-cell subtype distribution was quantified after 24 h. TCM: central memory T cells; TEM: effector
memory T cells; TEMRA: effector memory-CD45RA
+ T cells; TE: effector T cells; TExh: exhausted T cells. b Bulk- and TCM-derived CD8
+ CAR-T cells
were co-incubated with CD19+ K562 target cells, and the % CARhi and EGFRt and CD25 expression levels among CARhi cells were quantified.
c Both the bulk- and TCM-derived populations separated into CAR
hi/CD25+ and CARlo/CD25−, with the TCM-derived sample showing higher CD25
expression overall. In both samples, a subpopulation of contaminating CAR− cells was also CD25+, possibly due to paracrine stimulation from CAR+
cells. d Target cell lysis was monitored over 5 days. Average values of triplicates are shown with error bars indicating ± 1 s.d.
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with CD19 CAR transgene, and sorted for CAR+ expres-
sion (Additional file 13: Figure S13B). Without further ex-
pansion, sorted CAR+ cells were co-incubated with CD19+
K562 target cells for 36 h. CARhi/CARlo bifurcation was
observed in both T-cell populations, but the TCM-derived
population yielded more CARhi cells, and its CARhi cells
had higher CAR and CD25 expression levels (Fig. 10b).
Consistent with all previous experiments, which were per-
formed using bulk CD8+ T cells, CARlo cells from the
bulk CD8+-derived CAR-T sample were CD25−. In con-
trast, CARlo cells from the TCM-derived sample had par-
tially upregulated CD25 (Fig. 10c), indicating that the
TCM-derived cells are both primed for the CAR
hi pheno-
type and able to retain activation status even when CAR
expression levels are low. This conclusion is further sup-
ported by the observation that the TCM-derived cells were
much more effective at lysing the target cells (Fig. 10d).
We monitored the TCM status of the two populations
throughout the cell preparation process as well as after
antigen stimulation. Surface staining of CCR7 and CD45RA
revealed that most cells in the TCM-enriched population
had lost CCR7 expression by the time of cell sorting for
CAR expression (Additional file 14: Figure S14A), a pro-
gression that is consistent with previous reports of ex vivo
TCM cell expansion [15, 16]. However, antigen stimulation
caused a re-enrichment of the CCR7+/CD45RA− pheno-
type, particularly among CARhi cells (Additional file 14:
Figure S14B). In contrast, the bulk CD8+ T cell population
enriched for CCR7 expression through the course of
CD3/CD28 bead stimulation, and further increased CCR7
expression upon antigen stimulation (Additional file 14:
Figure S14CD). Taken together, these results indicate the
use of TCM cells as the starting population is conducive to
the production of functionally superior CAR-T cells, even
though the dominant phenotype remains fluid throughout
the course of T-cell expansion and antigen stimulation.
Discussion
Recent successes in CD19 CAR–T-cell trials have demon-
strated the remarkable therapeutic potential of CD19
CAR-T cells and fueled intense interest in the development
of CAR–T-cell therapies against additional tumor targets.
As CAR–T-cell technology moves beyond experimental
status, it is critical that effective cell-manufacturingprotocols and characterization methods are developed to
ensure robust and reproducible generation of CAR-T cells.
The various clinical trials completed thus far have
employed different T-cell manufacturing protocols unique
to each research group, and the relative merits of each have
been judged based on overall clinical outcome rather than
a detailed examination of differences in T-cell characteris-
tics. It is also difficult to elucidate whether any particular
step in the preparation process may have affected the
phenotype and functionality of the resulting CAR-T cells.
As a result, efforts to improve cell preparation protocols
remain empirically driven, with few guiding cues on which
parameters to modify.
Here, we presented a systematic study on the pheno-
typic and functional changes of CAR-T cells after T-cell
activation. We demonstrated that activated T cells show a
clear pattern of population bifurcation into CARhi/CD25+
vs. CARlo/CD25− groups. This bifurcation appears to be
general to T cells activated in vitro, as it is observed in
both CD4+ and CD8+ T cells, in T cells stimulated through
either TCRs or CARs targeting different antigens, and in
T cells expressing CARs that contain either CD28 or
4-1BB co-stimulatory signals. The transient increase of
CAR expression upon antigen stimulation has been ob-
served in previous studies [29, 30], but to our knowledge,
no detailed characterization of the difference between
CARhi and CARlo cells has been performed. In this study,
we discovered that CARhi cells consistently upregulate ex-
pression of the activation marker CD25, and target-cell
lysis, cytokine production, and T-cell proliferation assays
demonstrate that CARhi/CD25+ cells are functionally su-
perior to their CARlo/CD25− counterparts. In fact, CARlo/
CD25− cells show multiple signs of anergy and are un-
able to execute anti-tumor functions. This observation is
of practical importance because the CARlo/CD25− popu-
lation is CAR+ with similar CAR genomic copy numbers
as CARhi cells; thus, they would have satisfied the release
criteria typically applied in CAR–T-cell trials [4, 31] des-
pite their lack of effector functions. The ability to distin-
guish and characterize this population was contingent
upon the detailed in vitro examination of T-cell phenotype
changes post stimulation.
Our results show that the CARhi/CD25+ phenotype is
a transient response to antigen stimulation rather than a
genetically hard-wired population destined for superior
Chang et al. Journal of Translational Medicine  (2015) 13:161 Page 13 of 16function. Past studies have demonstrated that T-cell ac-
tivation can temporarily enhance transgene expression
from constitutive promoters, but have not revealed the
underlying mechanisms [32, 33]. A scan of the EF1α
promoter used in the current study and in multiple clin-
ical trials [31, 34, 35] reveals binding sequences for
TFII-I and Sp1, both widely employed transcription fac-
tors. In particular, TFII-I has been shown to be rapidly
phosphorylated upon CD3 crosslinking and upregulated
in activated CD4+ T cells [36, 37]. It is possible that
T-cell signaling increases the level of these transcription
factors and results in the upregulation of CAR expres-
sion from the EF1α promoter. Further investigations are
necessary to conclusively elucidate the mechanism of
transient CAR upregulation upon antigen stimulation.
Although CARhi/CD25+ cells eventually return to a
CARlo/CD25− phenotype after antigen removal, they
mount a robust cytolytic and cytokine-production re-
sponse when re-challenged with antigen-expressing tar-
gets. This is in stark contrast to CARlo/CD25− cells,
which remain non-functional upon re-exposure to anti-
gen. Therefore, the ability to bias CAR-T cells toward
the CARhi/CD25+ phenotype during the cell-preparation
stage has the potential to increase the therapeutic cap-
ability of T cells against targeted tumor cells. We dem-
onstrated that, for a second-generation CAR containing
CD28 co-stimulatory domain, the application of extra
co-stimulation via agonistic CD28 antibody does not
alter the relative distribution of the CARhi vs. CARlo
subpopulations, but sustained antigen stimulation shows
strong correlations with CARhi cell generation. Interes-
tingly, the absolute density of antigen on target cells did
not correlate with the intensity of T-cell response or the
effectiveness of CARhi cell generation. Among the
antigen-presenting cells tested, CD19+ K562 and TM-LCL
appear to present levels of antigen stimulation that are
conducive to robust CARhi/CD25+ cell production, con-
sistent with TM-LCL’s successful use in clinical protocols
[23, 38]. It remains possible that characteristics in addition
to persistence, such as co-stimulatory signals present on
the target cell surface, contribute to the effectiveness of
CD19+ K562 and TM-LCL in supporting the generation
of CARhi cells. Given the apparent sensitivity of CARhi cell
production to the type and duration of antigen presenta-
tion, and the multiple degrees of variability that exist
among potential feeder cell lines used in ex vivo T-cell ex-
pansion, the detailed in vitro characterization approach
described in this studymay be used to systematically fine-tune
the antigen-presenting cell type and E:T ratio required for the
efficient production of functionally superior CAR-Tcells.
In addition to the type and degree of antigen stimulation
used to expand CAR-T cells, the specific T-cell subtype
used to generate CAR-T cells also greatly influences the ef-
ficiency of CARhi cell generation. Our study demonstratedthat CARhi cells are enriched in the TCM phenotype, and
TCM-derived CAR-T cells are functionally superior to those
made from bulk CD8+ T cells. These observations are con-
sistent with the previously reported observation that TCM
cells are superior to TEM cells in establishing long-term per-
sistence in primates [15]. In this and most other CAR–T-
cell characterization studies, in vivo results are viewed as
the most relevant and credible proof of CAR function. Al-
though the value of in vivo data is clear, many important
features of CAR-T cell biology—particularly dynamic
changes over time in phenotype and function—are impos-
sible to obtain at high enough resolution in vivo. Features
such as CARlo cells cannot be detected in animal models or
patients because they are quickly depleted in vivo, but the
knowledge of their existence and detailed in vitro charac-
terizations of such populations provide valuable informa-
tion on how to improve CAR-T cell production so as to
maximize the number of cells that will persist and execute
antitumor functions upon adoptive transfer.
Recent clinical studies have demonstrated the exciting
potential of checkpoint inhibitor therapies such as CTLA-4
and PD-1 blockade, which boost T-cell responses by
preventing T-cell exhaustion and anergy. Our observa-
tion that the CARhi phenotype is triggered by antigen
stimulation and maintained by prolonged antigen ex-
posure raised the question of whether CARhi cells may
be susceptible to exhaustion or dysfunction. We indeed
observed significant and sustained PD-1 upregulation
among CARhi cells. However, no functional impairment
was observed even when CARhi cells were challenged
over multiple days with a constant supply of target cells
that strongly overexpress PD-L1. It should be noted that
the K562 target cells used in this study do not express
the co-stimulatory molecules CD83, CD86, 4-1BB lig-
and, OX40 ligand, and ICOS ligand, and they express
very low levels of CD80 [39]. Past studies have needed
to engineer increased expression of these co-stimulatory
molecules on K562s in order to prime and expand
T cells [39–41]. Therefore, the K562 cells used in our
study, which have not been engineered to express
co-stimulatory molecules, are unlikely to significantly
mitigate PD-1/PD-L1 signaling via CAR-independent
co-stimulation. Our results contrast with reports of
PD-L1 sensitivity exhibited by T cells stimulated via natu-
ral TCRs [42–44], and indicate an unexpected source of
resilience in CAR-T cells against PD-1–mediated cell in-
activation. Intensive T-cell stimulation with CD3 and
CD28 antibodies has been found to overcome PD-1/
PD-L1 inhibition of T-cell proliferation in vitro [45]; it is
possible that robust expression and activation of the ex-
ogenous CAR containing a CD28 co-stimulatory domain
similarly overwhelms PD-1 signaling. However, PD-L1
blockade has been reported to restore activity in hypo-
functional CAR-T cells ex vivo after recovery from
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play a role in maintaining the dysfunction of exhausted
CAR-T cells. Since PD-1 blockade can indirectly impact
CAR-T cell function (e.g., by reducing the prevalence of
myeloid derived suppressor cells in the tumor micro-
environment [47]), co-administration of CAR-T cell
therapy with CTLA-4 or PD-1 blockade remains an
intriguing therapeutic option. Nevertheless, our results
suggest that PD-1 upregulation—even when sustained
over days in the presence of PD-L1–expressing target
cells—does not automatically relegate CAR-T cells to
anergy or exhaustion.Conclusions
In this study, we have identified and characterized a pat-
tern of population bifurcation that results in two distinct
T-cell groups with dramatic differences in proliferative and
anti-tumor capacities post antigen stimulation. The com-
bination of CAR and CD25 expression levels reliably pre-
dicts the functionality of a given T-cell population, thus
providing a convenient and robust set of phenotypic
markers that can aid future efforts to optimize T-cell
manufacturing protocols. Characterization results in our
study indicate that starting with an enriched TCM popula-
tion and carefully tuning the persistence of antigen stimu-
lation during the manufacturing stage may direct the T-cell
population toward the functionally superior phenotype,
and minimize a source of variability in T-cell quality that is
largely undetectable through standard product-release
testing and in vivo models. As adoptive T-cell therapy
makes strides in clinical outcomes, it is increasingly im-
portant that robust and reproducible T-cell manufacturing
protocols be optimized in a systematic manner. Additional
in-depth characterization studies on the phenotypic changes
experienced by T cells throughout the manufacturing and
post-infusion period will yield valuable information and guide
the continuing effort to improve adoptive T-cell therapy.Additional files
Additional file 1: Figure S1. EGFRt expression directly correlates with
CAR expression. CD8+ T cells were transduced with a cd19 car-t2a-egfrt
construct containing the CH2 and CH3 domains in the IgG4 spacer to
allow for anti-Fc antibody binding. (A) Unsorted transduced cells, (B)
sorted, resting CAR-T cells, (C) CAR-T cells co-incubated with parental
K562 cells, and (D) CAR-T cells co-incubated with CD19+ K562 targets
cells were co-stained with Erbitux and anti-Fc antibodies that bind to
EGFRt and the CAR extracellular spacer, respectively.
Additional file 2: Figure S2. CD4+ CAR-T cells polarize into CARhi and
CARlo populations. CD4+ T cells bifurcate into CARhi/CD25+ and CARlo/CD25−
populations upon co-incubation with on-target K562 cells for 24 h.
Additional file 3: Figure S3. Antigen-stimulated CD4+ as well as mixed
CD4+ and CD8+ CAR-T cells demonstrate an initial population crash
followed by selective expansion of CARhi cells. (A) CD4+ or (B) mixed
CD4+ and CD8+ CAR-T cells were co-incubated with parental and CD19+ K562
targets without exogenous cytokines and monitored for total T-cell count (leftaxis) and CARhi or CARlo as a proportion of total CAR-T cells (right axis).
Average values of triplicates are shown with error bars indicating ± 1 s.d.
Additional file 4: Figure S4. CD4+ CARhi and CARlo T cells exhibit
distinct functional capabilities. Sorted CD4+ CARhi and CARlo cells were
co-incubated with CD19+ K562 targets without exogenous cytokines and
monitored for (A) viable target-cell count, (B) viable T-cell count, and (C)
cytokine production after 24 h of co-incubation. Sorted CARlo values are
from single samples due to the rarity of viable cells recovered for this
population from cell sorting. For all other samples, average values of triplicates
are shown with error bars indicating ± 1 s.d.
Additional file 5: Figure S5. Isolation of CAR-T cell populations with
different CAR expression levels. Transduced, non–antigen-stimulated
CD8+ T cells were sorted by FACS into three populations with different
EGFRt expression levels (Low, Mid, and High). The y-axis is an irrelevant
channel and cells were not stained with DAPI.
Additional file 6: Figure S6. Additional CD28 co-stimulation does not
impact the CARhi response. CD8+ CAR-T cells co-incubated with CD19+
K562 target cells at 2:1 E:T ratio with or without CD28 agonist were monitored
for proportion and total number of CARhi cells. Average values of triplicates
are shown with error bars indicating ± 1 s.d. The difference in the number of
CARhi cells at 120 h was determined to be not significant (n.s.) by the
two-tailed unpaired Student’s t test with the Bonferroni correction (p= 0.0376,
which is greater than the 0.0125 significance level after the Bonferroni
correction for multiple comparisons).
Additional file 7: Figure S7. CAR and CD25 upregulation are directly
correlated in antigen-stimulated T cells. CAR-T cells bifurcate into CARhi/
CD25+ and CARlo/CD25− subpopulations upon co-incubation with CD19+
K562, TM-LCL, CD19+ H9, and Raji target cells for 24 h. JeKo-1 cells were
rapidly eliminated and did not elicit a CARhi response.
Additional file 8: Figure S8. CD19 expression levels of various target
cell lines. CD19+ H9, CD19+ K562, Raji, JeKo-1, TM-LCL, and parental K562
cell lines were stained with an anti-CD19 antibody or an isotype control.
Numbers above each plot indicate the fold difference in median fluorescence
intensity between CD19 and isotype control staining.
Additional file 9: Figure S9. Stimulating CAR-T cells with varying
amounts of irradiated CD19+ K562s impacts the dynamics of the CARhi
response. (A) Number of CARhi and (B) median CD25 expression among
CARhi cells in a co-incubation of CD8+ CAR-T cells with irradiated CD19+
K562 cells at various E:T ratios. Average values of triplicates are shown
with error bars indicating ± 1 s.d.
Additional file 10: Figure S10. PD-L1 can be overexpressed on
otherwise PD-L1− K562 target cells. (A) Various K562 target cell lines were
stained with PD-L1 antibody. (B) K562 lines were also cross-stained for
both PD-L1 and CD19 to verify antigen expression.
Additional file 11: Figure S11. CARhi cells upregulate CD25, Tim-3, and
PD-1 regardless of PD-L1 expression on target cells. CD8+ CAR-T cells were
co-incubated with CD19+ or CD19+PD-L1+ target cells without exogenous
cytokines and surface-stained with EGFRt, CD25, Tim-3, and PD-1 antibodies.
Additional file 12: Figure S12. CD4+ CARhi T cells express higher levels
of PD-1 than CD8+ CARhi T cells. CD4+ and CD8+ CAR-T cells were
co-incubated with CD19+ target cells without exogenous cytokines
and monitored by surface antibody staining for (A) % PD-1+ among
CARhi cells and (B) median PD-1 fluorescence among PD-1+ cells.
Average values of triplicates are shown with error bars indicating ± 1 s.d.
Additional file 13: Figure S13. Isolation of TCM-derived CAR
+ cells. (A)
The TCM subset (CD45RA
−, CCR7+) was enriched from bulk CD8+ T cells.
(B) Both TCM and bulk CD8
+ cells were transduced with CAR and sorted
for the EGFRt+ fraction. Both positive (solid gray) and negative (dotted
open) fractions were collected by magnetic bead sorting. Numbers
shown indicate the frequency of EGFRt+ cells within the positive fraction.
Additional file 14: Figure S14. Phenotypic shifts in the TCM- and bulk-
CD8–derived cells. (A) CD45RA and CCR7 surface expression was
monitored for TCM-derived cells prior to sorting for EGFRt
+ cells, 4 days
after sorting (immediately before co-incubation with target cells), and
after 36 h of co-incubation with CD19+ target cells. (B) EGFRt and CCR7
surface expression after 36 h of co-incubation with CD19+ target cells.
(C) and (D) show the corresponding data for bulk-CD8–derived cells.
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